# Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

> **NCT01064505** · PHASE1 · COMPLETED · sponsor: **Quark Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Optic Atrophy
- Non-arteritic Anterior Ischemic Optic Neuropathy

## Interventions

- **DRUG:** QPI-1007 at various doses

## Key facts

- **NCT ID:** NCT01064505
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064505, "Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01064505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*